- Home
- ESQ vs PHAT Comparison
ESQ vs PHAT Comparison
Compare ESQ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESQ | PHAT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.0M | 894.0M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESQ | PHAT |
|---|---|---|
| Price | $106.23 | $10.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $120.33 | $19.83 |
| AVG Volume (30 Days) | 77.9K | ★ 957.7K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | 14.20 | ★ 42.72 |
| EPS | ★ 5.87 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $28.65 | $92.15 |
| Revenue Next Year | $4.95 | $59.79 |
| P/E Ratio | $18.18 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $69.14 | $2.21 |
| 52 Week High | $119.86 | $18.31 |
Technical Indicators
Market Signals| Indicator | ESQ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 41.81 |
| Support Level | $91.62 | $10.06 |
| Resistance Level | $106.32 | $12.62 |
| Average True Range (ATR) | 3.71 | 0.67 |
| MACD | 0.28 | 0.07 |
| Stochastic Oscillator | 49.56 | 25.26 |
Price Performance
Historical ComparisonAbout ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.